<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>SALVAX- salicylic acid aerosol, foam </strong><br>Quinnova Pharmaceuticals, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>
<span class="Bold">SALVAX<br></span>Hydrating Topical Foam<br>(salicylic acid in a water and lipid based foam, 6%)<br><br><span class="Bold">Rx Only</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_c1af0392-63c6-4be3-9a74-556c2efc49f4"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">SALVAX is applied topically and used in the removal of excessive keratin in hyperkeratotic <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span>. Each gram of SALVAX contains salicylic acid 6% as the active ingredient, and the following inactive ingredients: dimethicone, ethylparaben, glycerin, methylcellulose, methylparaben, phenoxyethanol, polyoxyl 40 stearate, polysorbate 20, polysorbate 80, povidone, propylene glycol, propylparaben, purified water, sodium citrate, sodium hydroxide, stearic acid, and trolamine and in propellants butane and propane.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fe9e41f3-8641-4a48-9972-25e49dcadbfd"></a><a name="section-1.1"></a><p></p>
<h2>CHEMICAL STRUCTURE</h2>
<p class="First">Salicylic acid is the 2-hydroxy derivative of benzoic acid having the following chemical structure:</p>
<div class="Figure">
<img alt="chemical-structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=879e31b4-3449-40ce-9b34-815563d4e272&amp;name=salvax-1.jpg"><p class="MultiMediaCaption">salvax-img-01</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_99ec0706-0673-4eff-9ff8-a3e3ee23da88"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Salicylic acid has been shown to produce <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span> of the horny layer of skin while not affecting qualitative or quantitative changes in structure of the viable epidermis. The mechanism of action has been attributed to dissolution of intercellular cement substance. In a study of the percutaneous absorption of salicylic acidfrom SALVAX infour patients with extensive active <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, Taylor and Halprin showed that peak serum salicylate levels never exceeded 5 mg/100 ml even though more than 60% of the applied salicylic acid was absorbed. Systemic toxic reactions are usually associated with much higher serum levels(30 to 40mg/100ml). Peak serum levels occurred within 5 hours of the topical application under occlusion. The sites were occluded for 10 hours over the entire body surface below the neck. Since salicylates are distributed in the extracellular space, patients with a contracted extracellular space due to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> or diuretics have higher salicylate levels than those with a normal extracellular space. (See PRECAUTIONS). </p>
<p>The major metabolites identified in the urine after topical administration are salicyluric acid (52%), salicylate glucuronides (42%), and free salicylic acid (6%). The urinary metabolites after percutaneous absorption differ from those after oral salicylate administration; those derived from percutaneous absorption contain more glucuronides and less salicyluric and salicylic acid.  Almost 95% of a single dose of salicylate is excreted within 24 hours of its entrance into the extracellular space. </p>
<p>Fifty to eighty percent of salicylate is protein bound to albumin. Salicylates compete with the binding of several drugs and can modify the action of these drugs. By similar competitive mechanisms other drugs can influence the serum levels of salicylate. (See PRECAUTIONS).</p>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_9a384428-7c17-40c5-875a-40d3ef6d82bc"></a><a name="section-2.1"></a><p></p>
<h2>PHARMACOKINETICS</h2>
<p class="First">The mechanism of action of topically applied salicylic acid has been attributed to the dissolution of intercellular cement substance. </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_5cc16a15-4e86-4c85-a31d-09f878d9d522"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For Dermatologic Use: SALVAX is a topical aid in the removal of excessive keratin in hyperkeratotic <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span>, including verrucae and the various ichthyoses, <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">keratosis</span> palmaris and plantaris, <span class="product-label-link" type="condition" conceptid="4197127" conceptname="Keratosis pilaris">keratosis pilaris</span>, pityriasis rubra pilaris, and <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. </p>
<p>For Podiatric Use: SALVAX is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_e33efcf0-dcd8-4105-8e1a-1ad6b1a91c34"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">SALVAX should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. SALVAX should not be used in children under 2 years of age.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_d09a7de6-5a65-42db-bf6c-9e929270eeb7"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">SALVAX is for external use only. It is not for ophthalmic, oral, anal or intravaginal use. Contact with eyes, lips, broken or inflamed skin, and all mucous membranes should be avoided. SALVAX should not be used by persons who have a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to salicylic acid or any of the other listed ingredients. </p>
<p>Prolonged use over large areas, especially in children and those patients with significant renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> could result in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">salicylism</span>. Concomitant use of other drugs which may contribute to elevated serum salicylate levels should be avoided where the potential for toxicity is present.  In children under 12 years of age and those patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the area to be treated should be limited and the patient monitored closely for signs of salicylate toxicity: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of hearing, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperpnoea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span>. In the event of salicylic acid toxicity, the use of SALVAX should be discontinued.  Fluids should be administered to promote urinary excretion. Treatment with sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (oral or intravenous) should be instituted as appropriate. </p>
<p>Considering the potential risk of developing Reye’s syndrome, salicylate products should not be administered to children or teenagers with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> or <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, unless directed by a physician.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_8137ca07-db61-4565-8413-a903bae9f52e"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">SALVAX should be used only as directed by a physician and should not be used to treat any condition other than that for which it is prescribed. SALVAX should not be used on any skin area where <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or exudation is present as increased absorption may occur. If <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or irritation occurs, discontinue use and consult with prescribing physician.</p>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_84371627-78de-47c2-b5ac-2b402f312be4"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First">I. Due to the competition of salicylate with other drugs forbinding to serum albumin the following drug interactions may occur:</p>
<table width="393px">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> <span class="Bold">Drug</span>
</td>
<td> <span class="Bold">Description of Interaction</span>
</td>
</tr>
<tr>
<td> Tolbutamide; Sulfonylureas </td>
<td> <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> potentiated</td>
</tr>
<tr>
<td> Methotrexate</td>
<td>Decreases tubular reabsorption; clinical toxicity from methotrexate can result</td>
</tr>
<tr class="Last">
<td> Oral Anticoagulants</td>
<td> Increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></td>
</tr>
</tbody>
</table>
<p>II. Drugs changing salicylate levels by altering renal tubular reabsorption:</p>
<table width="402px">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> <span class="Bold">Drug</span>
</td>
<td><span class="Bold"> Description of Interaction</span></td>
</tr>
<tr>
<td> Corticosteroids            </td>
<td>Decreases plasma salicylate level; tapering doses of steroids may promote <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">salicylism</span></td>
</tr>
<tr class="Last">
<td> Ammonium Sulfate</td>
<td><p class="First">Increases plasma salicylate level </p></td>
</tr>
</tbody>
</table>
<p>III. Drugs with complicated interactions with salicylates:</p>
<table width="406px">
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> <span class="Bold">Drug                            </span>
</td>
<td> <span class="Bold">Description of Interaction</span>
</td>
</tr>
<tr>
<td> Heparin</td>
<td>Salicylate decreases platelet adhesiveness and interferes with hemostasis in heparin­-treated patients</td>
</tr>
<tr>
<td> Pyrazinamide</td>
<td>Inhibits pyrazinamide-­induced <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span></td>
</tr>
<tr class="Last">
<td> Uricosuric Agents</td>
<td>Effect of probenecid, sulfinpyrazone and phenylbutazone inhibited</td>
</tr>
</tbody>
</table>
<p>The following alterations of laboratory tests have been reported during salicylate therapy:</p> <table>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> <span class="Bold">Laboratory Tests    </span>
</td>
<td> <span class="Bold">Effects of Salicylates                                                        </span>
</td>
</tr>
<tr>
<td> Thyroid Function</td>
<td> Decreased PBI; increased T<span class="Sub">3</span> uptake</td>
</tr>
<tr>
<td> Urinary Sugar</td>
<td> False negative with glucose oxidase; false positive with Clinitest with high­dose salicylate  therapy (2­-5 g qd)</td>
</tr>
<tr>
<td> 5 Hydroxyindole AceticAcid</td>
<td> False negative with fluorometric test</td>
</tr>
<tr>
<td> Acetone, <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">Ketone Bodies</span></td>
<td> False positive FeCl<span class="Sub">3</span> inGerhardt reaction; red color persists with boiling</td>
</tr>
<tr>
<td> 17-­OH Corticosteroids</td>
<td> False reduced values with &gt;4.8 g qd salicylate</td>
</tr>
<tr>
<td> Vanilmandelic Acid</td>
<td> False reduced values</td>
</tr>
<tr>
<td> Uric Acid</td>
<td> May increase or decrease depending on dose</td>
</tr>
<tr class="Last">
<td> <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span></td>
<td> Decreased levels; slightly increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_4bcd96fb-2c4c-4b9b-8d11-1d6406801813"></a><a name="section-6.2"></a><p></p>
<h2><span class="Italics">Pregnancy (Category C)</span></h2>
<p class="First">Salicylic acid has been shown to be teratogenic in rats and monkeys. It is difficult to extrapolate from oral doses of acetylsalicylic acid used in these studies to topical administration as the oral dose to monkeys may represent 4 times the maximum daily human dose of salicylic acid (as supplied in one tube, 40 g of SALVAX) when applied topically over a large body surface. There are no adequate and well ­controlled studies in pregnant women. SALVAX should be used during pregnancy only if the potential benefit justifies the risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_f8d1e0cb-d512-4c1d-813e-34b8f045d88d"></a><a name="section-6.3"></a><p></p>
<h2><span class="Italics">Nursing Mothers</span></h2>
<p class="First">It is not known whether topically applied salicylic acid is excreted in human milk. Due to the fact that many drugs are excreted in human milk, caution should be exercised by physicians when administering SALVAX to nursing mothers and nursing mothers should certainly not apply SALVAX to the chest area or any other part of the body with which the nursing child’s mouth is likely to come in contact.</p>
<p>Because of the potential for serious adverse reactions in nursing infants from the mother’s use of SALVAX, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_96571c74-98a0-4cdd-a975-1f75c1e82641"></a><a name="section-6.4"></a><p></p>
<h2><span class="Italics">Carcinogenesis, Mutagenesis, Impariment of Fertility</span></h2>
<p class="First">No data are available concerning potential carcinogenic or reproductive effects of SALVAX.  It has been shown to lack mutagenic potential in the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> test.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8258682f-c896-41f1-8c7c-b30e9d9b2e6a"></a><a name="section-6.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">KEEP THIS AND ALL OTHER MEDICATIONS OUT OF THE REACH OF CHILDREN. </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_2e7e28b5-c9db-4eb0-9099-d233f1e91357"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or irritation is possible. <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">Peeling</span> of the skin may increase as the salicylic acid works to loosen excess keratin. If excessive burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> occurs, discontinue use and consult your physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_089cd888-a336-4168-9b32-f44bab13f4b6"></a><a name="section-8"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">DOSAGE - See WARNINGS</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_bb612d16-e309-4611-b23b-742faf4f24d9"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Unless otherwise directed by a prescribing physician, SALVAX should be applied to affected area twice a day. SALVAX should be rubbed into the skin until it is completely absorbed. </p>
<p><span class="Bold">SALVAX should be shaken vigorously before each application and inverted to administer.</span></p>
<div class="Figure">
<img alt="canister-inversion" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=879e31b4-3449-40ce-9b34-815563d4e272&amp;name=salvax-2.jpg"><p class="MultiMediaCaption">salvax-img-02</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_1221152b-edad-4c12-8539-748a3d4ccc63"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">SALVAX is supplied in a 70 gram or 2.5 ounce aerosolized canister bearing the NDC Number 23710-­006­-70, a 200 gram or 7.1 ounce aerosolized canister bearing the NDC Number 23710­-006­-02, a 22 gram or 0.79 ounce aerosolized canister bearing the NDC Number 23710-006-20, and a 10 gram or 0.36 ounce aerosolized canister bearing the NDC Number 23710­-006­-01. The 10 gram canister is a physician­ dispensed sample product. </p>
<p>Store at controlled room temperature 15° - 25°C (59° - 77°F). </p>
<p>Contains flammable materials. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose to temperatures over 120°F (48°C) even when empty. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_94e93874-2687-4e2d-8ed1-ee8ee3dfa6ef"></a><a name="section-11"></a><p></p>
<h1></h1>
<p class="First">U.S. PATENT PENDING FOR SALVAX.</p>
<p>SALVAX is manufactured for Quinnova Pharmaceuticals, Inc., Newtown, PA 18940, (877) 660-6263, www.QUINNOVA.com</p>
<p>Prescribing Information as of April 2009.</p>
<p>SALVX014    4/09</p>
<div class="Figure">
<img alt="company-logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=879e31b4-3449-40ce-9b34-815563d4e272&amp;name=salvax-3.jpg"><p class="MultiMediaCaption">salvax-img-03</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_1920b30f-1be7-4ce6-b16d-397c9bbe97e4"></a><a name="section-12"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="product-label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=879e31b4-3449-40ce-9b34-815563d4e272&amp;name=salvax-4.jpg"></div>
<div class="Figure"><img alt="folding-carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=879e31b4-3449-40ce-9b34-815563d4e272&amp;name=salvax-5.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SALVAX 		
					</strong><br><span class="contentTableReg">salicylic acid aerosol, foam</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:23710-006</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SALICYLIC ACID</strong> (SALICYLIC ACID) </td>
<td class="formItem">SALICYLIC ACID</td>
<td class="formItem">3.88 g  in 70 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIMETHICONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYOXYL 40 STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 20</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROLAMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ETHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHENOXYETHANOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTANE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:23710-006-01</td>
<td class="formItem">10 g in 1 CANISTER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:23710-006-02</td>
<td class="formItem">200 g in 1 CANISTER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:23710-006-20</td>
<td class="formItem">22 g in 1 CANISTER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:23710-006-70</td>
<td class="formItem">70 g in 1 CANISTER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">UNAPPROVED DRUG OTHER</td>
<td class="formItem"></td>
<td class="formItem">01/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Quinnova Pharmaceuticals, Inc.
							(607183766)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>57bebd43-67af-461e-8e7f-43f131c7df64</div>
<div>Set id: 879e31b4-3449-40ce-9b34-815563d4e272</div>
<div>Version: 7</div>
<div>Effective Time: 20100625</div>
</div>
</div> <div class="DistributorName">Quinnova Pharmaceuticals, Inc.</div></p>
</body></html>
